Literature DB >> 28583922

Modafinil in schizophrenia: is the risk worth taking?

Daniel Neto1,2, Carla Spínola1, Joaquim Gago1,2.   

Abstract

Schizophrenia is a severe mental disorder characterised by positive and negative symptoms. Negative symptoms are difficult to treat and there is no specific treatment. In small trials, modafinil has been studied in association with antipsychotic treatment. We present three cases of its use; two have developed positive symptoms and one developed renal impairment. Further studies are needed to assess its usefulness in schizophrenia and safety in this group of patients. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  drugs: psychiatry; schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28583922      PMCID: PMC5534665          DOI: 10.1136/bcr-2017-219218

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  25 in total

Review 1.  Negative symptoms: the 'pathology' of motivation and goal-directed behaviour.

Authors:  R G Brown; G Pluck
Journal:  Trends Neurosci       Date:  2000-09       Impact factor: 13.837

2.  Modafinil modulates anterior cingulate function in chronic schizophrenia.

Authors:  Sean A Spence; Russell D Green; Iain D Wilkinson; Mike D Hunter
Journal:  Br J Psychiatry       Date:  2005-07       Impact factor: 9.319

3.  Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.

Authors:  Serge Sevy; Murray H Rosenthal; Jose Alvir; Sabina Meyer; Hema Visweswaraiah; Handan Gunduz-Bruce; Nina R Schooler
Journal:  J Clin Psychiatry       Date:  2005-07       Impact factor: 4.384

Review 4.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

Authors:  Michael F Green; Robert S Kern; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

Review 5.  The molecular genetics of cognition: dopamine, COMT and BDNF.

Authors:  J Savitz; M Solms; R Ramesar
Journal:  Genes Brain Behav       Date:  2006-06       Impact factor: 3.449

6.  Impact of modafinil on prefrontal executive function in schizophrenia.

Authors:  Michael D Hunter; Venkatasubramanian Ganesan; Iain D Wilkinson; Sean A Spence
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

7.  Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.

Authors:  Danielle C Turner; Luke Clark; Edith Pomarol-Clotet; Peter McKenna; Trevor W Robbins; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2004-07       Impact factor: 7.853

8.  Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial.

Authors:  Tom F D Farrow; Michael D Hunter; Rozana Haque; Sean A Spence
Journal:  Br J Psychiatry       Date:  2006-11       Impact factor: 9.319

9.  Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia.

Authors:  Murray H Rosenthal; Sharon L Bryant
Journal:  Clin Neuropharmacol       Date:  2004 Jan-Feb       Impact factor: 1.592

10.  A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia.

Authors:  Joseph M Pierre; John H Peloian; Donna A Wirshing; William C Wirshing; Stephen R Marder
Journal:  J Clin Psychiatry       Date:  2007-05       Impact factor: 4.384

View more
  1 in total

Review 1.  Modafinil in the rehabilitation of a patient with post-surgical posterior fossa syndrome: a lesson to be learned?

Authors:  Emanuela Molinari; Maria Oto; Ashita Waterston; Natasha Fullerton
Journal:  Cerebellum Ataxias       Date:  2019-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.